학술논문

Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans
Document Type
article
Source
Alzheimer's & Dementia. 11(7)
Subject
Biomedical and Clinical Sciences
Biological Psychology
Clinical Sciences
Neurosciences
Psychology
Dementia
Genetics
Prevention
Human Genome
Alzheimer's Disease
Aging
Neurodegenerative
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Brain Disorders
Biotechnology
Acquired Cognitive Impairment
2.1 Biological and endogenous factors
Aetiology
2.6 Resources and infrastructure (aetiology)
Detection
screening and diagnosis
4.1 Discovery and preclinical testing of markers and technologies
Neurological
Alzheimer Disease
Apolipoproteins E
Biomarkers
Cognitive Dysfunction
Databases
Bibliographic
Disease Progression
Genetic Association Studies
Humans
Membrane Transport Proteins
Mitochondrial Precursor Protein Import Complex Proteins
Neuroimaging
Alzheimer's disease
Mild cognitive impairment
Genome-wide association studies
Next generation sequencing
Copy number variation
Magnetic resonance imaging
Positron emission tomography
Cerebrospinal fluid
DNA
RNA
Memory
Cognition
Bioethical issues
Precision medicine
Alzheimer's Disease Neuroimaging Initiative
Geriatrics
Clinical sciences
Biological psychology
Language
Abstract
IntroductionGenetic data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) have been crucial in advancing the understanding of Alzheimer's disease (AD) pathophysiology. Here, we provide an update on sample collection, scientific progress and opportunities, conceptual issues, and future plans.MethodsLymphoblastoid cell lines and DNA and RNA samples from blood have been collected and banked, and data and biosamples have been widely disseminated. To date, APOE genotyping, genome-wide association study (GWAS), and whole exome and whole genome sequencing data have been obtained and disseminated.ResultsADNI genetic data have been downloaded thousands of times, and >300 publications have resulted, including reports of large-scale GWAS by consortia to which ADNI contributed. Many of the first applications of quantitative endophenotype association studies used ADNI data, including some of the earliest GWAS and pathway-based studies of biospecimen and imaging biomarkers, as well as memory and other clinical/cognitive variables. Other contributions include some of the first whole exome and whole genome sequencing data sets and reports in healthy controls, mild cognitive impairment, and AD.DiscussionNumerous genetic susceptibility and protective markers for AD and disease biomarkers have been identified and replicated using ADNI data and have heavily implicated immune, mitochondrial, cell cycle/fate, and other biological processes. Early sequencing studies suggest that rare and structural variants are likely to account for significant additional phenotypic variation. Longitudinal analyses of transcriptomic, proteomic, metabolomic, and epigenomic changes will also further elucidate dynamic processes underlying preclinical and prodromal stages of disease. Integration of this unique collection of multiomics data within a systems biology framework will help to separate truly informative markers of early disease mechanisms and potential novel therapeutic targets from the vast background of less relevant biological processes. Fortunately, a broad swath of the scientific community has accepted this grand challenge.